
    
      To confirm the safety and tolerability of the Maximum Tolerated Dose (MTD) of 131I-chTNT-1/B
      MAb given as a single interstitial infusion in patients with glioblastoma multiforme at first
      relapse.

      To estimate overall survival, progression free survival and proportion of patients alive at
      six months after treatment.
    
  